What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Disease
Transplantation, Internal medicine, Hematopoietic stem cell transplantation, Surgery and Immunology are his primary areas of study.
His studies deal with areas such as Transplantation Conditioning, Stem cell and Chemotherapy as well as Transplantation.
His Internal medicine research incorporates themes from Gastroenterology and Oncology.
Mohamad Mohty works mostly in the field of Hematopoietic stem cell transplantation, limiting it down to concerns involving Intensive care medicine and, occasionally, Cancer and Clinical trial.
The study incorporates disciplines such as Cumulative incidence and Hazard ratio in addition to Surgery.
His research investigates the connection between Immunology and topics such as Progenitor cell that intersect with issues in Plerixafor.
His most cited work include:
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (453 citations)
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach (275 citations)
- Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories (243 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Surgery.
His study connects Gastroenterology and Internal medicine.
His Gastroenterology study combines topics in areas such as Total body irradiation and Bone marrow.
His research integrates issues of Regimen, Stem cell and Immunology in his study of Transplantation.
His Oncology research focuses on Multiple myeloma and how it relates to Dexamethasone.
His Hematopoietic stem cell transplantation research integrates issues from Survival rate, Transplantation Conditioning, Human leukocyte antigen and Retrospective cohort study.
He most often published in these fields:
- Internal medicine (80.72%)
- Transplantation (74.98%)
- Oncology (36.68%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (80.72%)
- Transplantation (74.98%)
- Oncology (36.68%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Transplantation, Oncology, Acute leukemia and Gastroenterology.
His work is connected to Myeloid leukemia, Cyclophosphamide, Hematopoietic stem cell transplantation, Incidence and Hazard ratio, as a part of Internal medicine.
He is involved in the study of Transplantation that focuses on Graft-versus-host disease in particular.
Mohamad Mohty has researched Oncology in several fields, including Refractory, Chemotherapy, Cohort, Regimen and Multiple myeloma.
The concepts of his Acute leukemia study are interwoven with issues in Multivariate analysis, Marrow transplantation and Lymphoblastic Leukemia.
His studies deal with areas such as Progressive disease, Human leukocyte antigen and Cumulative incidence as well as Gastroenterology.
Between 2019 and 2021, his most popular works were:
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease (74 citations)
- Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (63 citations)
- COVID-19 outcomes in patients with hematologic disease. (59 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Mohamad Mohty mostly deals with Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Disease.
Many of his studies on Internal medicine apply to Gastroenterology as well.
Mohamad Mohty studies Graft-versus-host disease, a branch of Transplantation.
His Oncology study incorporates themes from Refractory, Chemotherapy, Lymphoma, Chimeric antigen receptor and Multiple myeloma.
His Hematopoietic stem cell transplantation research is multidisciplinary, relying on both Hematology, Pandemic and Retrospective cohort study.
His study in Disease is interdisciplinary in nature, drawing from both Metagenomics, Randomized controlled trial and Immunology, Vaccination.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
